報告摘要

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg. Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share. The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share. Report Scope This report quantifies the global Neuromyelitis Optica Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032. It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neuromyelitis Optica Drug. Key Companies & Market Share Insights This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking. Neuromyelitis Optica Drug Market by Company Pfizer Fresenius Teva Sandoz Intas Gyjtrs NANG KUANG Tianjin Kingyork Baxter CSL Grifols Octapharma CBOP Neuromyelitis Optica Drug Segment by Type Glucocorticoids Immunotherapies Others Neuromyelitis Optica Drug Segment by Application Acute Attack Remission Prophylactic Treatment Neuromyelitis Optica Drug Segment by Region North America United States Canada Mexico Europe Germany France U.K. Italy Spain Russia Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Middle East & Africa Saudi Arabia Israel United Arab Emirates Turkey Iran Egypt Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. Reasons to Buy This Report 1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market. 2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Drug and provides them with information on key market drivers, restraints, challenges, and opportunities. 3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition. 4. This report stays updated with novel technology integration, features, and the latest developments in the market 5. This report helps stakeholders to gain insights into which regions to target globally 6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Drug. 7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution. Chapter Outline Chapter 1: Research objectives, research methods, data sources, data cross-validation; Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 6: Detailed analysis of Neuromyelitis Optica Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc. Chapter 13: The main points and conclusions of the report.

目錄 Table of Contents

1 Preface 1.1 Scope of Report 1.2 Reasons for Doing This Study 1.3 Research Methodology 1.4 Research Process 1.5 Data Source 1.5.1 Secondary Sources 1.5.2 Primary Sources 2 Market Overview 2.1 Product Definition 2.2 Neuromyelitis Optica Drug by Type 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) 2.2.2 Glucocorticoids 2.2.3 Immunotherapies 2.2.4 Others 2.3 Neuromyelitis Optica Drug by Application 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) 2.3.2 Acute Attack 2.3.3 Remission Prophylactic Treatment 2.4 Assumptions and Limitations 3 Neuromyelitis Optica Drug Breakdown Data by Type 3.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2021-2026) 3.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2027-2032) 4 Neuromyelitis Optica Drug Breakdown Data by Application 4.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2021-2026) 4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2027-2032) 5 Global Growth Trends 5.1 Global Neuromyelitis Optica Drug Market Perspective (2021-2032) 5.2 Global Neuromyelitis Optica Drug Growth Trends by Region 5.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2021 VS 2025 VS 2032 5.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2021-2026) 5.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2027-2032) 5.3 Neuromyelitis Optica Drug Market Dynamics 5.3.1 Neuromyelitis Optica Drug Industry Trends 5.3.2 Neuromyelitis Optica Drug Market Drivers 5.3.3 Neuromyelitis Optica Drug Market Challenges 5.3.4 Neuromyelitis Optica Drug Market Restraints 6 Market Competitive Landscape by Players 6.1 Global Top Neuromyelitis Optica Drug Players by Revenue 6.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2021-2026) 6.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2021-2026) 6.2 Global Neuromyelitis Optica Drug Industry Players Ranking, 2023 VS 2024 VS 2025 6.3 Global Key Players of Neuromyelitis Optica Drug Head Office and Area Served 6.4 Global Neuromyelitis Optica Drug Players, Product Type & Application 6.5 Global Neuromyelitis Optica Drug Manufacturers Established Date 6.6 Global Neuromyelitis Optica Drug Market CR5 and HHI 6.7 Global Players Mergers & Acquisition 7 North America 7.1 North America Neuromyelitis Optica Drug Market Size (2021-2032) 7.2 North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 7.3 North America Neuromyelitis Optica Drug Market Size by Country (2021-2026) 7.4 North America Neuromyelitis Optica Drug Market Size by Country (2027-2032) 7.5 United States 7.5 United States 7.6 Canada 7.7 Mexico 8 Europe 8.1 Europe Neuromyelitis Optica Drug Market Size (2021-2032) 8.2 Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 8.3 Europe Neuromyelitis Optica Drug Market Size by Country (2021-2026) 8.4 Europe Neuromyelitis Optica Drug Market Size by Country (2027-2032) 8.5 Germany 8.6 France 8.7 U.K. 8.8 Italy 8.9 Spain 8.10 Russia 8.11 Netherlands 8.12 Nordic Countries 9 Asia-Pacific 9.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2021-2032) 9.2 Asia-Pacific Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 9.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Country (2021-2026) 9.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Country (2027-2032) 9.5 China 9.6 Japan 9.7 South Korea 9.8 India 9.9 Australia 9.10 China Taiwan 9.11 Southeast Asia 10 South America 10.1 South America Neuromyelitis Optica Drug Market Size (2021-2032) 10.2 South America Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 10.3 South America Neuromyelitis Optica Drug Market Size by Country (2021-2026) 10.4 South America Neuromyelitis Optica Drug Market Size by Country (2027-2032) 10.5 Brazil 10.6 Argentina 10.7 Chile 10.8 Colombia 10.9 Peru 11 Middle East & Africa 11.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2021-2032) 11.2 Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 11.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021-2026) 11.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2027-2032) 11.5 Saudi Arabia 11.6 Israel 11.7 United Arab Emirates 11.8 Turkey 11.9 Iran 11.10 Egypt 12 Players Profiled 12.1 Pfizer 12.1.1 Pfizer Company Information 12.1.2 Pfizer Business Overview 12.1.3 Pfizer Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.1.4 Pfizer Neuromyelitis Optica Drug Product Portfolio 12.1.5 Pfizer Recent Developments 12.2 Fresenius 12.2.1 Fresenius Company Information 12.2.2 Fresenius Business Overview 12.2.3 Fresenius Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.2.4 Fresenius Neuromyelitis Optica Drug Product Portfolio 12.2.5 Fresenius Recent Developments 12.3 Teva 12.3.1 Teva Company Information 12.3.2 Teva Business Overview 12.3.3 Teva Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.3.4 Teva Neuromyelitis Optica Drug Product Portfolio 12.3.5 Teva Recent Developments 12.4 Sandoz 12.4.1 Sandoz Company Information 12.4.2 Sandoz Business Overview 12.4.3 Sandoz Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.4.4 Sandoz Neuromyelitis Optica Drug Product Portfolio 12.4.5 Sandoz Recent Developments 12.5 Intas 12.5.1 Intas Company Information 12.5.2 Intas Business Overview 12.5.3 Intas Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.5.4 Intas Neuromyelitis Optica Drug Product Portfolio 12.5.5 Intas Recent Developments 12.6 Gyjtrs 12.6.1 Gyjtrs Company Information 12.6.2 Gyjtrs Business Overview 12.6.3 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.6.4 Gyjtrs Neuromyelitis Optica Drug Product Portfolio 12.6.5 Gyjtrs Recent Developments 12.7 NANG KUANG 12.7.1 NANG KUANG Company Information 12.7.2 NANG KUANG Business Overview 12.7.3 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.7.4 NANG KUANG Neuromyelitis Optica Drug Product Portfolio 12.7.5 NANG KUANG Recent Developments 12.8 Tianjin Kingyork 12.8.1 Tianjin Kingyork Company Information 12.8.2 Tianjin Kingyork Business Overview 12.8.3 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio 12.8.5 Tianjin Kingyork Recent Developments 12.9 Baxter 12.9.1 Baxter Company Information 12.9.2 Baxter Business Overview 12.9.3 Baxter Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.9.4 Baxter Neuromyelitis Optica Drug Product Portfolio 12.9.5 Baxter Recent Developments 12.10 CSL 12.10.1 CSL Company Information 12.10.2 CSL Business Overview 12.10.3 CSL Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.10.4 CSL Neuromyelitis Optica Drug Product Portfolio 12.10.5 CSL Recent Developments 12.11 Grifols 12.11.1 Grifols Company Information 12.11.2 Grifols Business Overview 12.11.3 Grifols Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.11.4 Grifols Neuromyelitis Optica Drug Product Portfolio 12.11.5 Grifols Recent Developments 12.12 Octapharma 12.12.1 Octapharma Company Information 12.12.2 Octapharma Business Overview 12.12.3 Octapharma Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.12.4 Octapharma Neuromyelitis Optica Drug Product Portfolio 12.12.5 Octapharma Recent Developments 12.13 CBOP 12.13.1 CBOP Company Information 12.13.2 CBOP Business Overview 12.13.3 CBOP Revenue in Neuromyelitis Optica Drug Business (2021-2026) 12.13.4 CBOP Neuromyelitis Optica Drug Product Portfolio 12.13.5 CBOP Recent Developments 13 Report Conclusion 14 Disclaimer

圖表清單 List of Tables & Figures

List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neuromyelitis Optica Drug Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021-2026) Table 7. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2027-2032) Table 9. Global Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021-2026) Table 11. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2027-2032) Table 13. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Neuromyelitis Optica Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Neuromyelitis Optica Drug Market Share by Region (2021-2026) Table 16. Global Neuromyelitis Optica Drug Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Neuromyelitis Optica Drug Market Share by Region (2027-2032) Table 18. Neuromyelitis Optica Drug Industry Trends Table 19. Neuromyelitis Optica Drug Industry Drivers Table 20. Neuromyelitis Optica Drug Industry Opportunities and Challenges Table 21. Neuromyelitis Optica Drug Market Restraints Table 22. Global Top Neuromyelitis Optica Drug Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Neuromyelitis Optica Drug Revenue Market Share by Players (2021-2026) Table 24. Global Neuromyelitis Optica Drug Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served Table 26. Global Neuromyelitis Optica Drug Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Neuromyelitis Optica Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Neuromyelitis Optica Drug Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Neuromyelitis Optica Drug Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Neuromyelitis Optica Drug Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Neuromyelitis Optica Drug Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Neuromyelitis Optica Drug Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Neuromyelitis Optica Drug Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Neuromyelitis Optica Drug Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Neuromyelitis Optica Drug Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2027-2032) & (US$ Million) Table 45. Pfizer Company Information Table 46. Pfizer Business Overview Table 47. Pfizer Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 48. Pfizer Neuromyelitis Optica Drug Product Portfolio Table 49. Pfizer Recent Developments Table 50. Fresenius Company Information Table 51. Fresenius Business Overview Table 52. Fresenius Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 53. Fresenius Neuromyelitis Optica Drug Product Portfolio Table 54. Fresenius Recent Developments Table 55. Teva Company Information Table 56. Teva Business Overview Table 57. Teva Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 58. Teva Neuromyelitis Optica Drug Product Portfolio Table 59. Teva Recent Developments Table 60. Sandoz Company Information Table 61. Sandoz Business Overview Table 62. Sandoz Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 63. Sandoz Neuromyelitis Optica Drug Product Portfolio Table 64. Sandoz Recent Developments Table 65. Intas Company Information Table 66. Intas Business Overview Table 67. Intas Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 68. Intas Neuromyelitis Optica Drug Product Portfolio Table 69. Intas Recent Developments Table 70. Gyjtrs Company Information Table 71. Gyjtrs Business Overview Table 72. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 73. Gyjtrs Neuromyelitis Optica Drug Product Portfolio Table 74. Gyjtrs Recent Developments Table 75. NANG KUANG Company Information Table 76. NANG KUANG Business Overview Table 77. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 78. NANG KUANG Neuromyelitis Optica Drug Product Portfolio Table 79. NANG KUANG Recent Developments Table 80. Tianjin Kingyork Company Information Table 81. Tianjin Kingyork Business Overview Table 82. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 83. Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio Table 84. Tianjin Kingyork Recent Developments Table 85. Baxter Company Information Table 86. Baxter Business Overview Table 87. Baxter Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 88. Baxter Neuromyelitis Optica Drug Product Portfolio Table 89. Baxter Recent Developments Table 90. CSL Company Information Table 91. CSL Business Overview Table 92. CSL Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 93. CSL Neuromyelitis Optica Drug Product Portfolio Table 94. CSL Recent Developments Table 95. Grifols Company Information Table 96. Grifols Business Overview Table 97. Grifols Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 98. Grifols Neuromyelitis Optica Drug Product Portfolio Table 99. Grifols Recent Developments Table 100. Octapharma Company Information Table 101. Octapharma Business Overview Table 102. Octapharma Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 103. Octapharma Neuromyelitis Optica Drug Product Portfolio Table 104. Octapharma Recent Developments Table 105. CBOP Company Information Table 106. CBOP Business Overview Table 107. CBOP Revenue in Neuromyelitis Optica Drug Business (2021-2026) & (US$ Million) Table 108. CBOP Neuromyelitis Optica Drug Product Portfolio Table 109. CBOP Recent Developments Table 110. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Neuromyelitis Optica Drug Product Image Figure 5. Global Neuromyelitis Optica Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Neuromyelitis Optica Drug Market Share by Type: 2025 VS 2032 Figure 7. Glucocorticoids Product Figure 8. Immunotherapies Product Figure 9. Others Product Figure 10. Global Neuromyelitis Optica Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Neuromyelitis Optica Drug Market Share by Application: 2025 VS 2032 Figure 12. Acute Attack Product Figure 13. Remission Prophylactic Treatment Product Figure 14. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Neuromyelitis Optica Drug Market Share by Region: 2025 VS 2032 Figure 17. Global Neuromyelitis Optica Drug Market Share by Players in 2025 Figure 18. Global Neuromyelitis Optica Drug Manufacturers Established Date Figure 19. Global Top 5 and 10 Neuromyelitis Optica Drug Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 23. United States Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 26. Europe Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 28. Germany Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 38. China Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 43. Australia Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 48. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Neuromyelitis Optica Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 54. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 55. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 56. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 57. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 58. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 59. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 60. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 61. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 62. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 63. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 64. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026) Figure 65. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021-2026)

Single User	$2,950 USD
Multi User	$4,430 USD
Enterprise	$5,900 USD

Neuromyelitis Optica Drug Industry Research Report 2026

授權報價

報告摘要

提及公司